Group 1 - The report by Zhong Chengxin Certification Research provides a comprehensive quantitative assessment of the diversity and inclusion (D&I) performance of 760 companies listed on the Hong Kong Stock Exchange with a market capitalization exceeding HKD 5 billion, using a framework that integrates ISO 30415:2021 standards and HKEX ESG guidelines [1][12][14] - The overall D&I performance of Hong Kong listed companies shows a pattern of "initial development with significant differentiation," with an average score of 48.52 out of 100 and a median score of 47.11, indicating that most companies are still in the early stages of D&I practices [1][13][41] - 28% of companies scored below 40, while 51% scored between 40 and 60, and only 7% exceeded a score of 70, highlighting the need for improvement in D&I practices across the market [1][41][44] Group 2 - Leading companies in D&I performance are primarily in the financial sector, with HSBC Holdings scoring 85.3 and AIA Group scoring 83.7, attributed to their strong governance, high levels of internationalization, and significant investment in human capital [1][13][52] - The report identifies common issues across the market, such as the lack of substantial equity indicators like "gender pay ratio" and low disclosure rates for data on employees with disabilities, indicating a gap in transparency and accountability [1][2][13] - The financial industry leads with an average score of 65.8, followed by non-bank financial services at 62.5, while sectors like real estate and electronics lag behind with scores of 45.6 and 43.2, respectively, reflecting significant industry disparities in D&I performance [2][13][56] Group 3 - The report suggests that companies should adopt ISO 30415 as a guideline to strengthen governance commitments, data-driven decision-making, and enhance transparency in disclosures [2][14] - Investors are encouraged to incorporate D&I assessments into their investment frameworks and conduct industry comparisons, as D&I performance is expected to become a key non-financial indicator of investment value in the Hong Kong capital market [2][14] - The findings indicate that the Hong Kong market is at a critical transition period for D&I practices, moving from mere compliance to creating strategic value, which is essential for gaining investor trust [2][14]

Core Viewpoint - The performance of innovative pharmaceutical companies in China for the first half of 2025 has been impressive, with significant revenue and profit growth driven by innovative drug sales, indicating a potential recovery in the pharmaceutical industry [1][6][15]. Group 1: Company Performance - Heng Rui Pharmaceutical achieved a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, with a net profit of 4.45 billion yuan, up 29.67%. Innovative drug sales accounted for 60.66% of total revenue [3][9]. - BeiGene reported total revenue of 17.52 billion yuan, a 46.0% increase year-on-year, with a net profit of 450 million yuan, marking a turnaround from losses [3][6]. - China Biopharmaceutical's revenue reached 17.57 billion yuan, a 10.7% increase, with innovative product revenue of 7.8 billion yuan, up 27.2%, representing 44.4% of total revenue [3][6]. - XinDa Biopharmaceutical achieved revenue of 5.95 billion yuan, a 50.6% increase, and a net profit of 1.21 billion yuan, turning a loss from the previous year [7][8]. - Xiansheng Pharmaceutical reported a revenue increase of 15.1% to 3.58 billion yuan, with innovative drug revenue surpassing 75% of total revenue [8]. Group 2: Market Trends - The rising proportion of innovative drug revenue among multiple pharmaceutical companies suggests a shift towards innovation-driven strategies, indicating a growing market for innovative drugs in China [6][8][15]. - The second-tier market is experiencing a prosperous phase, leading to speculation about a potential "spring" for the pharmaceutical industry, although the primary market remains challenging [4][15]. - The demand for high-quality products that can compete globally is increasing, with a focus on "best-in-class" products [4][15]. Group 3: Business Development (BD) Contributions - Business development (BD) activities are becoming crucial for the growth of innovative pharmaceutical companies, with significant deals contributing to revenue [9][10]. - Heng Rui Pharmaceutical's BD activities included a $1.97 billion contract with Merck and a partnership with GSK, highlighting the increasing global engagement of Chinese innovative drug companies [10][11]. - The first half of 2025 saw over 50 BD transactions in China's innovative drug sector, with a total disclosed cooperation amount exceeding $48.44 billion, marking a significant increase compared to the previous year [10][11]. Group 4: Challenges and Outlook - Despite the positive trends, companies face challenges such as intense market competition, high project uncertainty, and increasing accounts receivable [13][14]. - Some companies, like BeiDa TianHeng, reported significant revenue declines due to high R&D investments and previous income recognition from collaborations [13][14]. - Overall, the industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion phase [14][15].

Core Viewpoint - The performance of innovative pharmaceutical companies in China for the first half of 2025 is impressive, with significant revenue and profit growth driven by innovative drug sales, indicating a potential recovery in the pharmaceutical industry [1][3][10]. Summary by Sections Company Performance - Heng Rui Pharmaceutical achieved a revenue of 15.761 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.450 billion yuan, up 29.67%. Innovative drug sales accounted for 60.66% of total revenue [3][12]. - Bai Jie Shen Zhou reported total revenue of 17.518 billion yuan, a 46.0% increase, with a net profit of 450 million yuan, marking a turnaround from losses. The sales of its key products, including the BTK inhibitor and PD-1 inhibitor, significantly contributed to this growth [3][7]. - Xin Da Biotech achieved revenue of 5.953 billion yuan, a 50.6% increase, and a net profit of 1.213 billion yuan, compared to a loss in the previous year, driven by strong sales of its PD-1 inhibitor and new weight-loss drug [8]. - Xian Sheng Pharmaceutical reported a revenue increase of 15.1% to 3.585 billion yuan, with innovative drug revenue reaching 2.776 billion yuan, accounting for 77.4% of total revenue [9]. Market Trends - The rising proportion of innovative drug revenue among multiple pharmaceutical companies suggests a shift towards innovation-driven strategies, with increasing market demand for innovative products supported by healthcare policies [10][20]. - Business Development (BD) activities are becoming crucial for growth, with significant deals indicating a robust international presence for Chinese innovative drug companies [12][13]. Challenges and Outlook - Despite the positive trends, companies face challenges such as intense market competition, high project uncertainty, and increasing accounts receivable [18]. - Some companies, like Bai Li Tian Heng and Bei Da Pharmaceutical, reported declines in net profit due to high R&D costs and overdue payments to partners, highlighting the risks associated with innovation investments [18][19]. - Overall, the industry is transitioning from a low point to a recovery phase, with expectations for sustained growth in the innovative drug sector driven by efficiency and cost advantages [20].

Core Viewpoint - Hansoh Pharmaceutical reported strong financial performance for the first half of 2025, with significant growth in revenue and net profit driven by innovative drug sales and licensing income [1][2]. Financial Performance - In the first half of 2025, Hansoh Pharmaceutical recorded revenue of 7.434 billion yuan, a year-on-year increase of 14.3% - The net profit attributable to shareholders was 3.135 billion yuan, reflecting a year-on-year growth of 15.0% - Innovative drug sales and licensing income amounted to 6.145 billion yuan, accounting for 82.7% of total revenue [1]. Expense Analysis - Sales expenses reached 1.818 billion yuan, up 5.6% year-on-year - Research and development expenses were 1.441 billion yuan, increasing by 20.5% year-on-year - Management expenses decreased to 343 million yuan, down 3.1% year-on-year [1]. Business Segmentation - Revenue from different therapeutic areas included: oncology (4.531 billion yuan, 60.9%), infectious diseases (735 million yuan, 9.9%), central nervous system (768 million yuan, 10.4%), and metabolism/others (1.400 billion yuan, 18.8%) - The company focuses on oncology while also developing products in infectious diseases, central nervous system, and metabolism, creating a robust product matrix [1]. Clinical Pipeline - As of the mid-2025 report, the company has over 40 candidate innovative drug pipelines and is conducting more than 70 clinical trials, including 8 candidates entering clinical trials for the first time and 3 major products in phase 3 trials - The company is actively expanding indications for existing major products and advancing preclinical pipelines [2]. Business Development Opportunities - During the reporting period, the company received a confirmed upfront payment of 112 million USD from Merck, contributing to collaboration revenue - A collaboration agreement with Regeneron for HS-20094 was established, with an upfront payment of 80 million USD received, and a potential total transaction value of 1.93 billion USD [2]. Profit Forecast - The company expects net profits attributable to shareholders for 2025-2027 to be 5.021 billion, 5.567 billion, and 6.355 billion yuan, with year-on-year growth rates of 14.9%, 12.9%, and 12.1% respectively - Corresponding price-to-earnings ratios are projected to be 40, 35, and 31 times [3].

Core Viewpoint - The performance of innovative pharmaceutical companies in China has shown significant growth in the first half of 2025, with many companies reporting impressive revenue and profit increases driven by innovative drug sales [1][4][7]. Group 1: Company Performance - Heng Rui Pharmaceutical achieved a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67%, with innovative drug sales accounting for 60.66% of total revenue [1][8]. - BeiGene reported total revenue of 17.52 billion yuan, a 46.0% increase year-on-year, with a net profit of 450 million yuan, marking a turnaround from losses [1][4]. - Innovent Biologics achieved revenue of 5.95 billion yuan, a 50.6% increase, and a net profit of 1.21 billion yuan, compared to a loss of 160 million yuan in the previous year [5]. - Xiansheng Pharmaceutical reported a revenue increase of 15.1% to 3.58 billion yuan, with innovative drug revenue reaching 2.78 billion yuan, accounting for 77.4% of total revenue [6]. Group 2: Market Trends - The rising proportion of innovative drug revenue among multiple pharmaceutical companies indicates a successful shift towards innovation-driven strategies, with increasing market demand for innovative products [7][12]. - The Chinese innovative drug market is expanding, supported by improved public health awareness and favorable healthcare policies [7][12]. - Business development (BD) activities have become a crucial growth engine for innovative pharmaceutical companies, with significant increases in BD transactions in the first half of 2025 [9][10]. Group 3: Challenges and Future Outlook - Despite the positive trends, companies face challenges such as intense market competition, high project uncertainty, and increasing accounts receivable [12][13]. - The overall industry is transitioning from a low point, with profitability beginning to recover, indicating a shift from an "investment phase" to a "harvest phase" [12][14]. - Analysts predict that the innovative drug sector will continue to thrive, driven by high efficiency and low-cost development advantages, particularly in popular technology areas [12][14].

Investment Rating - The report maintains a "Recommended" investment rating for Hansoh Pharmaceutical (03692.HK) [1] Core Views - The company's revenue for the first half of 2025 reached 7.434 billion yuan, representing a year-on-year increase of 14.3%. Sales from innovative drugs and cooperative products amounted to approximately 6.145 billion yuan, up 22.1%, accounting for about 82.7% of total revenue [1] - Net profit for the same period was 3.135 billion yuan, reflecting a growth of 15.0%. Research and development expenses were approximately 1.441 billion yuan, an increase of 20.4%, constituting 19.4% of total revenue [1] - The report highlights the continuous advancement of the core pipeline and the robust growth driven by innovative drug revenues, with a focus on internationalization strategies [7] Financial Summary - Total revenue projections for 2025-2027 are estimated at 141.63 billion yuan, 155.41 billion yuan, and 179.87 billion yuan, with year-on-year growth rates of 15.5%, 9.7%, and 15.7% respectively [7] - The net profit for the same period is projected to be 51.88 billion yuan, 54.47 billion yuan, and 59.96 billion yuan, with growth rates of 18.7%, 5.0%, and 10.1% respectively [7] - The earnings per share (EPS) is expected to increase from 0.74 yuan in 2024 to 0.99 yuan in 2027 [9] Market Performance - The report indicates that the innovative drug revenue continues to rise, significantly contributing to the company's performance. The revenue breakdown includes 4.531 billion yuan from oncology, 735 million yuan from anti-infection, 768 million yuan from central nervous system, and 1.4 billion yuan from metabolic and other diseases [7] - The company has made significant progress in expanding its core products' indications, including new approvals for Amivantamab and the acceptance of applications for the indications of Inalizumab [7] Pipeline Development - The company is conducting over 70 clinical trials across more than 40 candidate innovative drugs, with 8 new candidates entering clinical trials during the reporting period [7] - Key registration phase III clinical trials include treatments for bone and soft tissue sarcoma, ovarian cancer, and moderate to severe plaque psoriasis [7]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 3.62% on August 29, with a trading volume of 2.004 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of August 28, 2024, the fund's latest share count was 6.619 billion, with a total size of 6.126 billion yuan, reflecting an increase of 1574.08% in shares and 1521.35% in size year-to-date [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 85.10% during the tenure [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's recent trading activity shows a cumulative trading amount of 34.226 billion yuan over the last 20 trading days, averaging 1.711 billion yuan per day [1]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.26% on August 28, with a trading volume of 2.227 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% per year and a custody fee of 0.10% per year [1] - As of August 27, 2024, the fund's latest share count was 6.506 billion shares, with a total size of 6.134 billion yuan, reflecting a year-to-date increase of 1545.50% in shares and 1523.46% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 88.56% during the tenure [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The fund's liquidity is strong, with a cumulative trading amount of 35.359 billion yuan over the last 20 trading days, averaging 1.768 billion yuan per day [1][2]

证券研究报告 医药生物 | 化学制药 港股|公司点评报告 hyzqdatemark 2025 年 08 月 28 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 市场表现： | 基本数据 | 2025 | 年 | 08 月 27 | | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 35.52 | | | 一年内最高/最低（港 | | | 39.76/15.96 | | | | 元） | | | | | | | 总市值（百万港元） | | | 215,078.93 | | | | 流通市值（百万港元） | | | 215,078.93 | | | | 资产负债率（%） | | | | 11.33 | | | 资料来源：聚源数据 | | | | | | 翰森制药(03692.HK) 投资评级： 买入（维持） ——创新收入高速增长，BD 收入有望贡献常态化增量 投资要点： 风险提示：临床研发失败风险，竞争格局恶化风险、销售不及预期风险等。 | 盈利预测与估值（人民币） | | ...

Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 1.23% as of August 28, 2025, with mixed performance among constituent stocks [3] - The Hang Seng Medical ETF (513060) fell by 1.15%, with a latest price of 0.69 yuan, but showed a 6.26% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) dropped by 1.02%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 0.81% to 0.98 yuan [4] Company Highlights - Innovent Biologics reported a 50.6% year-on-year revenue increase to 5.95 billion yuan for the first half of 2025, achieving a gross margin of 86% and a net profit of 830 million yuan, driven by pipeline expansion in oncology and new product launches [4] - The company has over 2 billion USD in cash reserves to support future innovation pipeline advancements [4] Policy and Industry Developments - The Ministry of Commerce and Jiangsu Provincial Government issued a plan to enhance the biopharmaceutical industry in Jiangsu Free Trade Zone by 2030, focusing on large molecule biologics, cell and gene therapy, and innovative medical devices [5] - Recent market pressure on the pharmaceutical sector was noted, with the Hang Seng Healthcare Index dropping over 2.1%, influenced by U.S. tariff proposals on imported drugs that could disrupt the global pharmaceutical industry [5] Analyst Insights - Analysts suggest that the recent decline in the Hong Kong pharmaceutical sector is a short-term fluctuation and does not alter the long-term industry outlook, with ongoing favorable policies expected to drive more cross-border business development transactions [6] - The Chinese innovative drug assets are gaining international recognition, presenting structural opportunities in the medium to long term [6] ETF Performance and Metrics - The Hang Seng Medical ETF has seen a significant increase in scale by 46.87 million yuan this month, ranking in the top third among comparable funds [8] - The ETF's share count increased by 92.5 million shares over the past week, also ranking in the top third [9] - The ETF recorded a net inflow of 74.96 million yuan recently, with a total of 65.92 million yuan accumulated over the last five trading days [10] - The ETF's financing net purchase reached 2.5072 million yuan this month, with a financing balance of 268 million yuan [11] Risk and Return Metrics - The Hang Seng Medical ETF has achieved a 48.60% net value increase over the past two years, with a maximum monthly return of 28.34% since inception [11] - The ETF's Sharpe ratio for the past year is 2.41, indicating strong risk-adjusted returns [12] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.63% year-to-date [13] Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Medical ETF is 30.9, which is below the historical average, indicating a potentially undervalued position [15]